303810 — Dongkook Life Science Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Dongkook Life Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	5,858	4,239	4,167	2,245	8,658
Depreciation
Amortisation
Non-Cash Items	3,208	2,888	5,667	11,374	9,618
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-10,489	-12,504	-17,725	-7,864	-24,253
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-1,424	-2,916	-4,608	11,536	434
Capital Expenditures	-28,664	-17,380	-4,791	-5,081	-5,691
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-1,620	-1,352	8,209	-2,276	-2,629
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-30,284	-18,731	3,418	-7,357	-8,319
Financing Cash Flow Items	-259	-1,169	-1,935	-2,072	-2,111
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	17,765	16,513	3,233	-5,199	7,535
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-13,883	-5,172	2,043	-1,021	-444